ASSESSING THE EFFICACY OF SYSTEMIC IMMUNOSUPPRESSIVE THERAPIES IN TREATING SEVERE ECZEMA. A SYSTEMATIC REVIEW AND META-ANALYSIS
Main Article Content
Keywords
Severe eczema, atopic dermatitis, systemic immunosuppressive therapy, biologics, JAK inhibitors, treatment efficacy, safety
Abstract
Background: Severe eczema refers to atopic dermatitis (AD) which results in long-lasting chronic inflammatory skin condition that creates severe effects on patient life quality. Systemic immunosuppressive therapies become essential for treating severe cases but they serve alongside topical treatments for treating mild-to-moderate conditions. The evaluation of both effectiveness and security outcomes for these treatments enables optimal medical treatment for patients.
Objectives: The present systematic assessment evaluates the treatment impact and safety levels of systemic immunosuppressive drugs for severe eczema as it reviews multiple therapeutic agents and presents evidence-backed clinical practice guidelines.
Methodology: The research examined databases of PubMed and Cochrane Library and Embase from the period between 2015 and 2024 for available studies. A research analysis included Randomized Controlled Trials (RCTs) and systematic reviews and meta-analyses of systemic immunosuppressive drugs which included cyclosporine along with methotrexate and azathioprine and mycophenolate mofetil and biologic therapeutics. The studies provided information about treatment effectiveness which included Eczema Area and Severity Index (EASI) scores together with Investigator's Global Assessment (IGA) and patient-reported outcomes and general security profiles.
Results: The selected studies numbered twenty-five. Brands such as dupilumab and JAK inhibitors including upadacitiniband abrocitinib exceeded expectations in their effectiveness and showed beneficial safety aspects above traditional immunosuppressant medicines that include cyclosporine and methotrexate. The traditional treatment approaches remained effective yet produced more adverse events that harmed the kidneys and liver functions. The addition of systemic therapy with topical corticosteroids as combination treatment yielded better results while minimizing new adverse reaction risks.
Conclusion: The management of serious eczema cases depends on systemic immunosuppression treatments. The therapeutic shift in eczema treatment now includes, biologic agents together with targeted therapies because they demonstrate superior efficacy and safety compared to traditional immunosuppressant. The selection of systemic treatments for patients requires clinicians to assess individual patient health conditions and their established therapeutic objectives.
References
2. Drucker, A. M., Ellis, A. G., Jabbar-Lopez, Z., & Nankervis, H. (2018). Systemic immunomodulatory treatments for atopic dermatitis: Protocol for a systematic review with network meta-analysis. BMJ Open, 8(8), e023061. https://bmjopen.bmj.com/content/ 8/8/e023061
3. Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., ... & Sidbury, R. (2014). Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology, 71(1), 116-132. https://jamanetwork.com/journals/jamadermatology/ fullarticle/2790388
4. Flohr, C., & Irvine, A. D. (2013). Systemic therapies for severe atopic dermatitis in children and adults. Journal of Allergy and Clinical Immunology, 132(3), 774-774.e6. https://www.jacionline.org/article/S0091-6749%2813%2900504-6/fulltext
5. Goujon, C., Viguier, M., Staumont-Sallé, D., Barbarot, S., Lasek, A., & Taïeb, A. (2018). Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: A phase III randomized noninferiority trial. Journal of Allergy and Clinical Immunology: In Practice, 6(2), 562-569.e3. https://jamanetwork.com/journals/jamadermatology/fullarticle/2790388
6. Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Armstrong, A. W., Thaçi, D., ... & Reich, K. (2021). Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. The Lancet, 397(10290), 2151-2168. https://jamanetwork.com/journals/jamadermatology/fullarticle/2790388
7. Meggitt, S. J., Gray, J. C., & Reynolds, N. J. (2006). Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial. The Lancet, 367(9513), 839-846. https://jamanetwork.com/journals/ jamadermatology/fullarticle/2790388
8. Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Worm, M., ... & Thaçi, D. (2021). Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 397(10290), 2169-2181. https://jamanetwork.com/journals/jamadermatology/fullarticle/2790388
9. Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink-Wagner, A., Gelmetti, C., ... & Wollenberg, A. (2012). Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. Journal of the European Academy of Dermatology and Venereology, 26(9), 1176-1193.
10. Sawangjit, R., Dilokthornsakul, P., Lloyd-Lavery, A., & Nankervis, H. (2020). Systemic treatments for eczema: A network meta-analysis. Cochrane Database of Systematic Reviews, 9(9), CD013206. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858. CD013206. pub2
11. Schmitt, J., Schäkel, K., Schmitt, N., & Meurer, M. (2007). Systemic treatment of severe atopic eczema: A systematic review. Acta Dermato-Venereologica, 87(2), 100-111. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-0207
12. Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Chamlin, S. L., ... & Elmets, C. A. (2014). Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology, 71(2), 327-349.
13. Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M. J., ... & Thaçi, D. (2020). Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396(10246), 255-266. https://jamanetwork.com/journals /jamadermatology/fullarticle/2790388
14. Thyssen, J. P., Vestergaard, C., Deleuran, M., & Bieber, T. (2020). European Task Force on Atopic Dermatitis (ETFAD): Treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 34(4), e167-e169.
15. Wang, C. Y., Ma, H., Song, Y., & Zhang, L. (2024). Efficacy and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescents: A systematic review and meta-analysis. Frontiers in Immunology, 15, Article 1245.
16. Wollenberg, A., Barbarot, S., Bieber, T., Christen-Zaech, S., Deleuran, M., Fölster-Holst, R., ... & Ring, J. (2009). ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 23(3), 317-328.
17. Wollenberg, A., Barbarot, S., Bieber, T., Christen-Zaech, S., Deleuran, M., Fölster-Holst, R., ... & Werfel, T. (2018). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. Journal of the European Academy of Dermatology and Venereology, 32(5), 657-682.
18. Wollenberg, A., Barbarot, S., Bieber, T., Christen-Zaech, S., Deleuran, M., Fölster-Holst, R., ... & Werfel, T. (2018). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. Journal of the European Academy of Dermatology and Venereology, 32(6), 850-878.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Arzu Khattak
Dubai Health Authority, Dubai, UAE
Moustafa H A Hamada
Dubai Hospital, Dubai, UAE
Latifa Al Abdal
Intern at EHS, RAK Hospitals, Dabai, UAE
Shaikha Mohammed M Alqahtani
Faculty of Medicine, Hacettepe University, Turkey
Shamsa Bin Bader Alaleeli
Sheikh Shakhboot Medical City, Abu Dhabi, UAE
Dhoha Mohamed Ahmed Alsalmi
Sheikh Shakhboot Medical City, Abu Dhabi, UAE
Reem Ahmed Abdelrahman Eldoma
Ahfad University For Women Khartoum, Sudan
Kuer Mabil
Ahfad University For Women, Sudan
Alqahtani Rose Fayiz M
Faculty of Medicine, Al-Baha University, Al-Baha
Sumayyah Leila Zaman
University of Sharjah, UAE
Nuha Yassir Jassim
Dubai Medical University, An Intern in Medcare Hospital, UAE